Identifying Attenuating Mutations: Tools for a New Vaccine Design against Flaviviruses
- PMID: 28869941
- DOI: 10.1159/000479966
Identifying Attenuating Mutations: Tools for a New Vaccine Design against Flaviviruses
Abstract
Emerging Flaviviruses pose an increasing threat to global human health. To date, human vaccines against yellow fever virus (YFV), Japanese encephalitis virus (JEV), dengue virus (DV), and tick-borne encephalitis virus (TBEV) exist. However, there is no human vaccine against other Flaviviruses such as Zika virus (ZIKV) and West Nile virus (WNV). In order to restrict their spread and to protect populations against the diseases they induce, vaccines against these emerging viruses must be designed. Obtaining new live attenuated Flavivirus vaccines using molecular biology methods is now possible. Molecular infectious clones of the parental viruses are relatively easy to generate. Key mutations present in live attenuated vaccines or mutations known to have a key role in the Flavivirus life cycle and/or interactions with their hosts can be identified by sequencing, and are then inserted in infectious clones by site-directed mutagenesis. More recently, the use of chimeric viruses and large-scale reencoding and introduction of microRNA target sequences have also been tested. Indeed, a combination of these methods will help in designing new generations of vaccines against emerging and reemerging Flaviviruses.
Keywords: Flavivirus vaccines; Live attenuated virus strains; MicroRNA target sequences; Molecular infectious clones.
© 2017 S. Karger AG, Basel.
Similar articles
-
Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis.Adv Virus Res. 2003;61:469-509. doi: 10.1016/s0065-3527(03)61013-4. Adv Virus Res. 2003. PMID: 14714441 Review.
-
T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species.J Virol. 2020 May 4;94(10):e00089-20. doi: 10.1128/JVI.00089-20. Print 2020 May 4. J Virol. 2020. PMID: 32132233 Free PMC article.
-
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.Vaccine. 2010 Jan 8;28(3):632-49. doi: 10.1016/j.vaccine.2009.09.098. Epub 2009 Oct 4. Vaccine. 2010. PMID: 19808029 Review.
-
DNA vaccines for flaviviruses.Adv Virus Res. 2003;61:445-68. doi: 10.1016/s0065-3527(03)61012-2. Adv Virus Res. 2003. PMID: 14714440 Review. No abstract available.
-
Stable and Highly Immunogenic MicroRNA-Targeted Single-Dose Live Attenuated Vaccine Candidate against Tick-Borne Encephalitis Constructed Using Genetic Backbone of Langat Virus.mBio. 2019 Apr 23;10(2):e02904-18. doi: 10.1128/mBio.02904-18. mBio. 2019. PMID: 31015334 Free PMC article.
Cited by
-
A systematic approach to the development of a safe live attenuated Zika vaccine.Nat Commun. 2018 Mar 12;9(1):1031. doi: 10.1038/s41467-018-03337-2. Nat Commun. 2018. PMID: 29531213 Free PMC article.
-
Anaplasma phagocytophilum modifies tick cell microRNA expression and upregulates isc-mir-79 to facilitate infection by targeting the Roundabout protein 2 pathway.Sci Rep. 2019 Jun 24;9(1):9073. doi: 10.1038/s41598-019-45658-2. Sci Rep. 2019. PMID: 31235752 Free PMC article.
-
A single-dose live attenuated chimeric vaccine candidate against Zika virus.NPJ Vaccines. 2021 Jan 29;6(1):20. doi: 10.1038/s41541-021-00282-y. NPJ Vaccines. 2021. PMID: 33514743 Free PMC article.
-
Flavivirus: From Structure to Therapeutics Development.Life (Basel). 2021 Jun 25;11(7):615. doi: 10.3390/life11070615. Life (Basel). 2021. PMID: 34202239 Free PMC article. Review.
-
An Attenuated Zika Virus Encoding Non-Glycosylated Envelope (E) and Non-Structural Protein 1 (NS1) Confers Complete Protection against Lethal Challenge in a Mouse Model.Vaccines (Basel). 2019 Sep 12;7(3):112. doi: 10.3390/vaccines7030112. Vaccines (Basel). 2019. PMID: 31547297 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources